KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Leases: 2023-2025

Historic Capital Leases for Aquestive Therapeutics (AQST) over the last 2 years, with Sep 2025 value amounting to $122,000.

  • Aquestive Therapeutics' Capital Leases fell 20.26% to $122,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $122,000, marking a year-over-year decrease of 20.26%. This contributed to the annual value of $146,000 for FY2024, which is 15.61% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Capital Leases stood at $122,000, which was down 6.15% from $130,000 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Capital Leases registered a high of $173,000 during Q4 2023, and its lowest value of $122,000 during Q3 2025.
  • Its 3-year average for Capital Leases is $148,625, with a median of $149,500 in 2024.
  • Data for Aquestive Therapeutics' Capital Leases shows a maximum YoY declined of 20.26% (in 2025) over the last 5 years.
  • Over the past 3 years, Aquestive Therapeutics' Capital Leases (Quarterly) stood at $173,000 in 2023, then decreased by 15.61% to $146,000 in 2024, then fell by 20.26% to $122,000 in 2025.
  • Its Capital Leases stands at $122,000 for Q3 2025, versus $130,000 for Q2 2025 and $138,000 for Q1 2025.